Next generation hypomethylating agent safe and active in MDS
In a phase II trial, Dr Guillermo Garcia-Manero (MD Anderson Cancer Center, Houston, USA) and colleagues evaluated treatment with guadecitabine (SGI-110), a next generation dinucleotide hypomethylating agent, in patients with higher risk myelodysplastic syndrome (MDS). They observed an overall response rate of 64%, including 23% of patients achieving complete remission. Median overall survival was 14 months. The most common adverse event was infection. “Guadecitabine is clinically active and safe in this cohort of patients with higher risk MDS and poor risk features”, concluded Garcia-Manero. Randomized studies are needed to directly compare guadecitabine to azacytidine and decitabine, the current standard of care.